The Price/Sales of Agios Pharmaceuticals Inc is 54.44
Price to sales ratio is a company’s stock price compared to its revenues.
ttm (trailing twelve months)
The price to sales ratio, Price/Sales ratio, P/S ratio, or PSR, is a valuation metric for stocks. It is calculated by dividing the company's market cap by the revenue in the most recent year. It can also be calculated by dividing the per-share stock price by per-share revenue. The price to sales ratio is for trailing twelve months so the reported sales are for the four previous quarters. Longer time periods can be examined at times.
A smaller price to sales ratio is usually thought to be a better investment since the investor is paying less for each unit of sales. However, sales do not reveal the whole picture, as the company may be unprofitable with a low P/S ratio. Because of the limitations, this ratio is usually used only for unprofitable companies, since they don't have a price to earnings ratio (P/E ratio). The metric can be used to determine the value of a stock relative to its past performance. It may also be used to determine relative valuation of a sector or the market as a whole.
Price to sales ratios vary greatly between sectors, so they are most useful in comparing similar stocks within a sector or sub-sector. Comparing P/S ratios carries the implicit assumption that all firms in the comparison have an identical capital structure.
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible